Sign In

Matthew Kirshner

Building New Biotech Ventures at Ferment

Matthew Kirshner is an early-stage company builder with a focus on using biotechnology to shape a healthier, more abundant, and engaging future.

His extensive background includes roles in pharma strategy consulting and drug development at Putnam Associates, business development and growth at Ginkgo Bioworks, and company creation in synthetic biology at Ferment.

At Ferment, Matthew is part of a venture studio that constructs biotech-driven companies leveraging top bio-platforms by uniting talent, capital, and innovative concepts.

He pursued his undergraduate studies in Economics and Global Health at Duke University.

Matthew Kirshner's previous experiences also include serving on the Investment Team at Ferment, contributing to growth and business development at Ginkgo Bioworks, and writing for SynbioMBA.

Moreover, he has held positions as a Senior Associate Consultant at Putnam Associates, a Portfolio Analyst Fellow at Duke University Office of Licensing and Ventures, and a Duke Shore Research Scholar at Duke University Center for Jewish Studies.

Highlights

Mar 6 · twitter

$xbi to one million

Feb 25 · twitter

The $LRMR news (and the lack of a market reaction) today is interesting since its among the first rare disease companies to announce Accelerated Approval alignment with the FDA since the Uniqure table-flip in November.

I would've thought announcing alignment under this new admin (particularly post-Uniqure) would be more significant (although I suspect folks just think they can still get stuffed at the goal-line once they're under review).

Matthew Kirshner
Add to my network

Location

New York, New York, United States